Skip to content

FDA OKs Roche pan-tumor liquid biopsy test

August 28, 2020

The FDA approves Roche (OTCQX:RHHBY) unit Foundation Medicine’s FoundationOne Liquid CDx, a comprehensive pan-tumor liquid biopsy test for solid tumors. The genomic profiling test analyzes more than 300 cancer-related genes and multiple genomic signatures based on circulating cell-free DNA in a blood sample using massively parallel sequencing to detect the four main classes of genomic alterations.

It is also approved as a companion diagnostic for Clovis Oncology’s (NASDAQ:CLVS) PARP inhibitor Rubraca (rucaparib) for certain prostate cancer patients and three first-line tyrosine kinase inhibitors for non-small cell lung cancer.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: